• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

B型血友病患者预防性治疗的益处。

The benefits of prophylaxis in patients with hemophilia B.

作者信息

Castaman Giancarlo

机构信息

a Center for Bleeding Disorders , Careggi University Hospital , Florence , Italy.

出版信息

Expert Rev Hematol. 2018 Aug;11(8):673-683. doi: 10.1080/17474086.2018.1489719. Epub 2018 Jul 18.

DOI:10.1080/17474086.2018.1489719
PMID:29909699
Abstract

The health benefits of prophylactic dosing regimens for clotting factor therapy in patients with hemophilia include reduced joint damage and improved quality of life; as such, prophylaxis is recommended in treatment guidelines. However, many patients with hemophilia B are treated on demand, and prophylaxis has been utilized less frequently than in hemophilia A. Areas covered: This review discusses the opportunities and evidence for prophylaxis in hemophilia B, in the context of treatment guidelines and with regard to factor IX (FIX) replacement therapies, including long-acting recombinant FIX (rFIX). Expert commentary: Long-acting rFIX concentrates may increase uptake of and adherence to prophylaxis regimens through attainment of higher trough levels with longer dosing intervals. In this new era of hemophilia B treatment, physicians may be able to achieve better clinical outcomes for their patients and reconsider treatment goals. Maintaining higher FIX trough levels will undoubtedly have long-term benefits for patients, such as preserving joint function. The long-acting rFIX concentrates support robust prophylaxis regimens and offer physician's flexibility in treating patients to best suit their needs, whether to enable an active lifestyle, to achieve higher trough levels for better bleed protection, or simply to decrease the burden of treatment by reducing injection frequency.

摘要

预防性给药方案用于血友病患者凝血因子治疗的健康益处包括减少关节损伤和改善生活质量;因此,治疗指南中推荐采用预防疗法。然而,许多B型血友病患者接受的是按需治疗,与A型血友病相比,预防疗法的使用频率较低。涵盖领域:本综述在治疗指南的背景下,讨论了B型血友病预防疗法的机会和证据,并涉及凝血因子IX(FIX)替代疗法,包括长效重组FIX(rFIX)。专家评论:长效rFIX浓缩剂通过延长给药间隔达到更高的谷浓度,可能会增加预防方案的采用率和依从性。在B型血友病治疗的新时代,医生或许能够为患者取得更好的临床疗效,并重新考虑治疗目标。维持较高的FIX谷浓度无疑将给患者带来长期益处,比如保留关节功能。长效rFIX浓缩剂支持强有力的预防方案,并为医生治疗患者提供灵活性,以最适合患者的需求,无论是实现积极的生活方式、达到更高的谷浓度以更好地预防出血,还是仅仅通过减少注射频率来减轻治疗负担。

相似文献

1
The benefits of prophylaxis in patients with hemophilia B.B型血友病患者预防性治疗的益处。
Expert Rev Hematol. 2018 Aug;11(8):673-683. doi: 10.1080/17474086.2018.1489719. Epub 2018 Jul 18.
2
BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.BAX326(重组凝血因子 IX)用于治疗和预防乙型血友病。
Expert Rev Hematol. 2014 Jun;7(3):333-42. doi: 10.1586/17474086.2014.903153.
3
Changing paradigm of prophylaxis with longer acting factor concentrates.长效因子浓缩物预防策略的转变。
Haemophilia. 2014 May;20 Suppl 4:99-105. doi: 10.1111/hae.12405.
4
Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.重组因子IX Fc融合蛋白与传统重组因子IX产品的持续预防治疗:疗效及每周因子用量比较
J Med Econ. 2017 Apr;20(4):337-344. doi: 10.1080/13696998.2016.1265973. Epub 2016 Dec 21.
5
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.转换为重组凝血因子IX融合蛋白(rIX-FP)的B型血友病患者的真实世界使用情况和出血率:一项回顾性国际分析。
Adv Ther. 2020 Jun;37(6):2988-2998. doi: 10.1007/s12325-020-01300-6. Epub 2020 Apr 24.
6
Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.通过凝血酶生成试验和因子IX活性监测B型血友病患者每周一次的重组因子IX预防治疗。
Int J Lab Hematol. 2017 Aug;39(4):359-368. doi: 10.1111/ijlh.12634. Epub 2017 Apr 13.
7
Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B.重组凝血因子IX用于B型血友病的预防、按需治疗及围手术期管理。
Expert Opin Biol Ther. 2018 Jan;18(1):95-100. doi: 10.1080/14712598.2018.1407311. Epub 2017 Nov 26.
8
Emerging drugs for hemophilia B.治疗乙型血友病的新型药物。
Expert Opin Emerg Drugs. 2014 Sep;19(3):407-14. doi: 10.1517/14728214.2014.946010. Epub 2014 Aug 6.
9
Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.系统评价和分析重组因子 IX 产品预防治疗乙型血友病与 rIX-FP 的疗效比较。
J Med Econ. 2019 Oct;22(10):1014-1021. doi: 10.1080/13696998.2019.1620246. Epub 2019 Jun 5.
10
GlycoPEGylated recombinant factor IX for hemophilia B in context.用于B型血友病的糖基化聚乙二醇化重组因子IX相关情况
Drug Des Devel Ther. 2018 Sep 11;12:2933-2943. doi: 10.2147/DDDT.S121743. eCollection 2018.

引用本文的文献

1
Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany.比较用于B型血友病的延长半衰期凝血因子IX(重组人凝血因子IX融合蛋白[rIX-FP]与重组人凝血因子IX聚乙二醇化[rFIXFc]和N9-糖蛋白[N9-GP])预防治疗的真实世界结果:来自德国的病历数据分析
Adv Ther. 2025 Sep 18. doi: 10.1007/s12325-025-03336-y.
2
Real-World Prophylaxis Outcomes with rIX-FP and rFIXFc for Males with Hemophilia B: Pooled Analysis of Medical Chart Data from Germany and Italy.rIX-FP和rFIXFc用于B型血友病男性患者的真实世界预防效果:德国和意大利病历数据的汇总分析
Adv Ther. 2025 Sep;42(9):4583-4596. doi: 10.1007/s12325-025-03303-7. Epub 2025 Jul 23.
3
Characteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX.
接受重组凝血因子IX治疗的B型血友病患者的特征及治疗模式
J Clin Med. 2025 Jun 26;14(13):4555. doi: 10.3390/jcm14134555.
4
Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies.英国血友病相关费用的分布和预测因素:CHESS I 和 CHESS II 疾病负担研究分析。
BMC Health Serv Res. 2024 Nov 20;24(1):1437. doi: 10.1186/s12913-024-11850-y.
5
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B.基于药代动力学模型的重度 B 型血友病因子 IX 预防治疗方案评估。
Sci Rep. 2024 Sep 4;14(1):20534. doi: 10.1038/s41598-024-70784-x.
6
Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: analysis of phase III trials using patient-reported outcomes.长期预防性使用重组人凝血因子VIII可改善甲型血友病患者的疼痛感知、心理健康和身体健康:使用患者报告结局对III期试验的分析
Ther Adv Hematol. 2024 Jul 30;15:20406207241257917. doi: 10.1177/20406207241257917. eCollection 2024.
7
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.B 型血友病无抑制剂患者使用重组凝血因子 IX Fc 预防治疗和按需治疗的成本效益分析。
Adv Ther. 2024 Jun;41(6):2307-2323. doi: 10.1007/s12325-024-02841-w. Epub 2024 Apr 23.
8
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.重组凝血因子IX与白蛋白连接融合蛋白(rIX-FP)在既往未治疗的B型血友病患者中的安全性和有效性
TH Open. 2024 Mar 26;8(1):e155-e163. doi: 10.1055/s-0044-1781466. eCollection 2024 Jan.
9
A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B.一项授权后安全性监测研究,旨在报告纯化因子IX浓缩物在乙型血友病儿科患者中的临床经验。
J Blood Med. 2024 Mar 5;15:113-122. doi: 10.2147/JBM.S425617. eCollection 2024.
10
Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.重组凝血因子 IX 白蛋白融合蛋白与重组凝血因子 IX Fc 融合蛋白每周预防性治疗乙型血友病的匹配调整间接比较。
Adv Ther. 2024 Feb;41(2):649-658. doi: 10.1007/s12325-023-02745-1. Epub 2023 Dec 9.